Research
Hormonal
ApoB and LDL particle number (measured by NMR) are superior predictors of cardiovascular risk and residual risk on therapy compared to LDL cholesterol or non-HDL cholesterol in patients with cardiometabolic risk.
If your LDL is 'normal' but you still have high cardiovascular risk (due to diabetes or high triglycerides), ask your doctor about ApoB or LDL particle number. These tests may better predict your risk and guide treatment adjustments, though they may not be covered by insurance.
GoodQualifiesHIGH confidence
In several epidemiological studies and in post hoc analyses of clinical trials, apoB has been found to be a better predictor of CVD risk than LDL cholesterol... particularly the on-treatment LDL cholesterol level... Measurements of apoB or LDL particle number by NMR may more closely quantitate the atherogenic lipoprotein load.
Why this rating
Supported by multiple epidemiological studies and post-hoc trial analyses, but limited by availability and cost of testing.
Source
Lipoprotein Management in Patients With Cardiometabolic Risk
John D. Brunzell et al. · Diabetes Care · 2008
DOI 10.2337/dc08-9018
clinical_guidelineCited 708×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lowering LDL cholesterol levels directly reduces the incidence of cardiovascular disease events, establishing a causal dose-response relationship where lower levels yield greater benefit.Strong
- In patients with high triglycerides or metabolic syndrome, non-HDL cholesterol is a superior predictor of cardiovascular risk and a valid secondary treatment target compared to LDL cholesterol alone.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →